WEB250 mg/month (one 5-mL injection of fulvestrant plus one 5-mL injection of placebo) with 500 mg/month (two 5-mL injections: 500 mg on days 0, 14, and 28 of month 1, then
Large-volume IM injections: A review of best practices
WEBThe CONFIRM study, a comparison trial of fulvestrant 250 mg/month (one 5-mL injection of fulvestrant plus one 5-mL injection of placebo) with 500 mg/month (two 5-mL injections: 500 mg on days 0 ...
Determining an effective route of administration for epinephrine: …
WEBApr 30, 2011 — In this study, Simons and colleagues concluded that the auto-injector (EpiPen) was equal to IM injection and superior to SQ. 1. However, this research cannot necessarily be generalized to the ...
Biosimilar Medications in Oncology: An Overview
WEBOct 22, 2021 — As of May 2021, 39 biosimilars of filgrastim, bevacizumab, trastuzumab, pegfilgrastim, and rituximab have been approved in the EU, and 14 oncology biosimilars were approved by the FDA for use in ...
Managing TSH Levels After Total Thyroidectomy
WEBSep 8, 2015 — For those who are considered to be low-risk patients, the recommendation is to maintain the serum TSH level just below the lower limit of the normal TSH range, 0.1 to 0.4 mU/ mL. 2 In high-risk ...
Clinically Significant Prostate Cancers Found Despite Low PSA
WEBApr 19, 2024 — Clinically significant prostate cancer is found in a “non-negligible” number of men who have screening PSA levels of 1.8 or higher but less than 3.0 ng/mL, according to recent study findings ...
Efficacy of Cathflo at suggested volume - Oncology Nurse Advisor
WEBMay 26, 2015 — The instructions for Cathflo are to instill 2 mg/2.2 mL solution into the port-a-cath. Wait 30 minutes, then check for blood return. If there is no blood return, the dose can be repeated in 120 ...
FDA Grants Accelerated Approval to Elrexfio for …
WEBAug 23, 2023 — Elrexfio is supplied as a ready-to-use solution in 76 mg/1.9 mL (40 mg/mL) and 44 mg/1.1 mL (40 mg/mL) single-dose vials. The solution does not require dilution prior to subcutaneous administration.
Epcoritamab Shows Promising Results in Multiply …
WEBAugust 27, 2024. During a median follow-up of 17.4 months, the ORR with epcoritamab was 82.0%. Epcoritamab, a CD3xCD20 bispecific antibody, demonstrated promising response rates among patients ...
Prostate-Specific Antigen (PSA) Test (Fact Sheet)
WEBMar 19, 2019 — In the past, most doctors considered PSA levels of 4.0 ng/mL and lower as normal. Therefore, if a man had a PSA level above 4.0 ng/mL, doctors would often recommend a prostate biopsy to determine ...